---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-262508"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:51:06.053006+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q3 revenue $21.8M (+20% YoY); raises FY2025 guidance to $84-86M

## Summary
- Q3 2025 revenue $21.8M, up 20% YoY; gross margin 81% (up 400 bps YoY).
- Net loss $8.7M, a 15% improvement YoY; Adjusted EBITDA loss $4.6M, improvement of 18%.
- Lung diagnostic testing revenue $19.8M (+16% YoY); Development Services $1.9M (+97% YoY).
- Raised FY2025 total revenue guidance to $84-86M from prior range.
- Cash $16.6M at Sept 30; accounts receivable increase $5.2M due to timing of collections.

## SEC filing metadata
- accession: 0001193125-25-262508
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000119312525262508/0001193125-25-262508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000119312525262508/bdsx-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-262508
- JSON: https://secwatch.observer/filing/0001193125-25-262508.json
- Plain text: https://secwatch.observer/filing/0001193125-25-262508.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.